Long term treatment for alopecia

A topical composition using extracts of Allium, Citrus, Paulinia, and Theobroma species addresses the limitations of existing alopecia treatments by providing sustained therapeutic effects for at least 24 weeks, ensuring safe and effective hair growth without relapse.

JP2024166033AActive Publication Date: 2024-11-28LEGACY HEALTHCARE (SWITZERLAND) SA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023186277
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2023-10-31
Publication Date
2024-11-28
Estimated Expiration
2043-10-31

AI Technical Summary

Technical Problem

Current treatments for alopecia, such as JAK inhibitors and corticosteroids, pose significant health risks and require strict adherence to withdrawal periods, leading to rapid disease relapse upon discontinuation, creating a debilitating cycle of hair growth and loss.

Method used

A topical composition comprising extracts of Allium, Citrus, Paulinia, and Theobroma species is administered to slow hair loss, stimulate hair growth, and increase density, with therapeutic effects lasting at least 24 weeks post-treatment.

Benefits of technology

The composition effectively treats and prevents alopecia with sustained efficacy for at least 24 weeks without requiring a washout period, reducing the risk of disease recurrence and side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024166033000003
    Figure 2024166033000003
  • Figure 2024166033000004
    Figure 2024166033000004
  • Figure 2024166033000001
    Figure 2024166033000001
Patent Text Reader

Abstract

To provide a topical composition for use in the treatment and / or prevention of alopecia of a subject, wherein the therapeutic effects persist for at least 24 weeks or more after the last administration of the composition, and also provide kits and methods of treating and / or preventing alopecia using the composition.SOLUTION: A composition for use in the treatment and / or prevention of alopecia of a subject comprises, as active ingredients, effective amounts of an extract of Allium species, an extract of Citrus species, an aqueous extract of Paullinia species and an extract of Theobroma species, wherein the composition is administered topically for a period of time necessary to detect one or more therapeutic effects consisting of slowing down the loss of hair, stimulating its growth and / or increasing the density of hair, and wherein the therapeutic effects persist for at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks or more after the last administration of the composition.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to topical compositions for use in treating and / or preventing hair loss in a subject, the therapeutic effect of which persists for at least 24 weeks or longer after the last administration of the composition. Also disclosed are kits and methods for treating and / or preventing hair loss using the compositions. [Background technology]

[0002] The hair follicle (HF) is a unique organelle that undergoes cyclical renewal throughout life. In healthy anagen HF subsections (the hair bulge and hair bulb) have relative immune privilege (IP), protecting the follicle from inflammatory processes and promoting immune tolerance. These distinct HF compartments are characterized by factors that act as IP protectors to safeguard the HF IP (Lintzeri, 2022).

[0003] As hair follicles develop, blood vessels originating from the deep dermal vascular network surround them. These blood vessels nourish the hair follicle and support its delivery of nutrients, waste evacuation, and growth (Murphey, 2022). The vasculature supports protective immune functions that protect the organism from pathogens and other pathogens by controlling the induction of migrating immune cells. In cases of inflammation or immune surveillance, cells lining the luminal sites of blood vessels, known as endothelial cells (ECs), attract migrating immune cells and guide them to the appropriate vascular exit sites, allowing the cells to enter the underlying tissue. Thus, "immunomodulatory ECs" (IMECs) (Amersfoort, 2022) play an important supportive role in the induction and directional migration of migrating immune cells. During inflammation, ECs expose various adhesion molecules on their surface that slow and halt the migration of immune cells in the blood circulation. These adhesion molecules are thought to provide guidance cues for immune cells to breach the vascular wall through a multistep process known as trans-endothelial migration (TEM) or migration (Schimmel, 2017).

[0004] In the normal hair cycle, only scattered immune cells are found around and occasionally within the hair bulb of anagen HFs (Lintzeri, 2022). However, in alopecia areata (AA), genetic or extrinsic factors induce a significant and unwanted transendothelial migration (TEM) of CD8+ T cells from the vasculature towards the hair follicle.

[0005] Histologically, AA lesions show a characteristic dense perifollicular and intrafollicular inflammatory cell infiltrate around the hair bulb region, resembling a bee swarm, forcing the HF into premature catagen, dystrophy, and ultimately apoptosis. CD8+ T cells are typically the first cells to invade the intrafollicular location, severely impairing the integrity of the HF (Lintzeri, 2022).

[0006] When AA recurs, the anagen phase of the hair cycle is significantly shortened, causing acute episodes of non-scarring alopecia ranging from small localized patchy areas on the scalp to complete hair loss on the scalp and body. Although the exact pathogenesis of AA has not yet been fully elucidated, it is recognized that IP disruption of the HF hair bulb plays an important role in the pathophysiology of the disease. The exact cause of IP disruption is not yet fully understood.

[0007] Local inflammation in AA is primarily mediated by the JAK-STAT pathway. In AA, there is an overexpression of inflammatory cytokines, which signal through their receptors via the JAK-STAT pathway. This leads to JAK-mediated production of IFN-γ and IL-15, which promotes an inflammatory feedback loop that further advances local inflammation. Given the critical role of the JAK-STAT pathway in mediating CD8+NKG2D+ T cell responses, a major driver of AA pathogenesis, it is not surprising that the drug class of JAK inhibitors, which inhibit JAK enzymes, blocks downstream signaling of different cytokines by interfering with the JAK-STAT signaling pathway, protecting hair follicles from damage and promoting the initiation of new anagen and hair regrowth (Dillon, 2021).

[0008] The first JAK inhibitor was approved for the treatment of AA in 2022, marking the first approved treatment for a debilitating chronic autoimmune disease, with more inhibitors in development (Dillon, 2021). Since the first JAK inhibitor was approved for the treatment of rheumatoid arthritis in 2011 (Shawky, 2022), real-world evidence of significant health-related risks has been collected (Hoisnard, 2022), leading to a class-wide black box warning for JAK inhibitors by the US Food and Drug Administration and the European Medicines Agency (Kragstrup, 2022).

[0009] Due to the significant risks associated with immunosuppression with JAK inhibitors, strict adherence to drug holiday periods is warranted.

[0010] However, because JAK inhibitors "simply" block the JAK-STAT signaling pathway, cessation of treatment leads to systematic rapid and complete relapse of the disease within 3 months (Askin, 2021). Tissue resident memory T cells (TRMs) are long-lived lymphocytes that reside in tissues and develop after the initiation of a T cell-mediated immune response. In fact, endothelial cells may promote the development of TRMs, as they are essential interaction partners for the migration of T cells into inflamed tissues. Wienke et al. have demonstrated that in a co-culture system of human cytokine-activated ECs and FACS-sorted T cells, the interaction of T cells with activated ECs stimulates tissue residence (Wienke, 2022). The relapse of AA, confirmation of upregulation of TRM cells, and reports of clinical benefit of JAK inhibitors during administration support the important role of TRM cells in the development of the disease (Ryan, 2021).

[0011] Until the first drug for AA is approved, standard treatment consists mainly of off-label use of corticosteroids in addition to older immunosuppressants (Meah, 2020). Unfortunately, corticosteroids, especially topical corticosteroids (TCS), have been reported to cause potential local side effects such as impaired epidermal barrier function and skin atrophy (Wollenberg, 2018). Additionally, percutaneous absorption of TCS through disrupted skin may cause systemic exposure and subsequent growth impairment (Coureau, 2008). As a result of both actual perceived side effects and potential long-term toxicity, “corticosteroid phobia” often leads to poor adherence to TCS (Stalder, 2017).

[0012] Similarly, the significant risks associated with corticosteroids warrant strict adherence to drug-free periods; however, similar to JAK inhibitors, disease relapse is common when treatment is discontinued (Lintzeri, 2021).

[0013] Systemic disease recurrence after treatment cessation turns AA patients' lives into a debilitating "emotional rollercoaster" that rhythmically alternates between periods of potential hair growth during treatment, followed by periods of hair loss after treatment cessation (McGettigan, 2013).

[0014] There is a high unmet medical need for treatments that are not only safe, but also do not require a drug holiday and have sustained efficacy after treatment is discontinued. Summary of the Invention

[0015] This object is achieved by providing a composition for use in the treatment and / or prevention of alopecia in a subject, comprising an effective amount of an extract of Allium spp., an extract of Citrus spp., an extract of Paulinia spp. and an extract of Theobrama spp. as active ingredients, The composition is administered topically for a period of time necessary to detect one or more therapeutic benefits, including slowing hair loss, stimulating hair growth, and / or increasing hair density; The one or more therapeutic effects persist for at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks or more after the last administration of the composition, as evidenced by measurement of the Severity of Alopecia Tool (SALT) score.

[0016] It is a further object of the present invention to provide a method for treating and / or preventing alopecia in a subject, the method comprising administering a composition comprising an effective amount of an extract of Allium spp., an extract of Citrus spp., an extract of Paulinia spp. and an extract of Theobrama spp. as active ingredients, The composition is administered topically for a period of time necessary to detect one or more therapeutic benefits, including slowing hair loss, stimulating hair growth, and / or increasing hair density; The one or more therapeutic benefits persist for at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks or more following the last administration of the composition, as evidenced by measurement of the Severity of Alopecia Tool (SALT) score.

[0017] A further object of the present invention is to provide the use of a composition of the present invention in the manufacture of a medicament for the treatment and / or prevention of alopecia in a subject.

[0018] A further object of the present invention is to provide a kit for the treatment and / or prevention of alopecia comprising the composition or compositions used according to the invention. [Brief description of the drawings]

[0019] [Figure 1] This is an example of SALT scoring (Olsen, ed., 2004). [Diagram 2] The SALT scores of patients treated with the composition continue to improve, with the changes in SALT scores continuing throughout the follow-up period and statistically significantly superior to placebo. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The publications and applications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publications by virtue of prior invention. Additionally, the materials, methods, and examples are illustrative only and are not intended to be limiting.

[0021] In case of conflict, the present specification, including definitions, shall prevail.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the subject matter of this specification belongs.As used herein, the following definitions are provided to facilitate understanding of the present invention.

[0022] The term "comprises / comprising" is generally used in the include / including sense, that is, permitting the presence of one or more features or components. The terms "comprise(s)" and "comprising" also encompass the more limited terms "consist(s)," "consisting of," and "consist / consisting essentially of," respectively.

[0023] As used in this specification and claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.

[0024] As used herein, the terms "subject" / "subject in need thereof" or "patient" / "patient in need thereof" are well known in the art and are used interchangeably herein and refer to mammals, including dogs, cats, rats, mice, monkeys, cows, horses, goats, sheep, pigs, camels, and most preferably humans. In some cases, the subject is a subject in need of treatment or a subject having a disease or disorder. However, in other embodiments, the subject may be a normal subject. The term does not indicate a particular age or sex. Thus, adult and neonatal subjects, both male and female, are intended to be covered. Preferably, the subject is a human, most preferably a human suffering from or at risk of suffering from alopecia.

[0025] The term "about," particularly in relation to a given amount, number, or percentage, is meant to encompass a deviation of plus or minus ten percent (±10). For example, about 5% encompasses any value between 4.5% and 5.5%, such as 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, or 5.5.

[0026] As used herein, "at least one" means "one or more," "two or more," "three or more," etc. For example, "at least eight weeks" means eight weeks or more, i.e., nine weeks, ten weeks, eleven weeks, etc.

[0027] In one aspect, the present invention provides a composition for use in the treatment and / or prevention of alopecia in a subject, said composition comprising as active ingredients an effective amount of an extract of an Allium species, an extract of a Citrus species, an extract of a Paullinia species and an extract of a Theobroma species, The composition is administered topically for a period of time necessary to detect one or more therapeutic benefits, including slowing hair loss, stimulating hair growth, and / or increasing hair density; The one or more therapeutic effects persist after the final administration of the composition, as evidenced by measurement of the Severity of Alopecia Tool (SALT) score.

[0028] In one embodiment, one or more therapeutic effects persist for at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks or more.

[0029] The terms "treatment" or "treating" refer to the administration of a composition, pharmaceutical composition, therapeutic agent, active ingredient, compound, etc. of the present disclosure to a subject for the purpose of: (i) inhibiting the disease, i.e. preventing the onset of clinical symptoms; (ii) reverse the disease; and / or (iii) relieving the disease, i.e., causing regression of clinical symptoms;

[0030] As used herein, the terms "prevention" or "preventing" refer to the administration of a composition, pharmaceutical composition, therapeutic agent, active ingredient, compound, etc. of the present disclosure to a subject for the purpose of preventing a disease, i.e., preventing the development of clinical symptoms and signs of a disease.

[0031] In the context of the present invention, the disease is alopecia. In one embodiment, the alopecia is an immune-mediated disease, preferably an autoimmune disease. More preferably, the autoimmune disease is alopecia areata.

[0032] Alopecia areata (AA) is an immune-mediated, autoimmune and inflammatory hair disease that affects both pediatric and adult patients. Immune inflammatory attack of scalp hair follicles aborts the normal hair cycle and causes hair follicles to enter telogen prematurely, resulting in alopecia. The disease begins with the development of perifollicular inflammation and infiltration of immune inflammatory cells around the hair bulb in anagen, leading to the breakdown of HF immune privilege, tissue dystrophy, HF cell death and hair shaft shedding (Lintzeri, 2022). A central role is played by NKG2D-positive T cells, natural killer (NK) cells and autoreactive CD8-positive T lymphocytes that recognize self-antigens upon exposure to MHC class I, class II expression on hair follicle cells. T cell activation is accompanied by increased IFN-γ secretion that recruits or activates more inflammatory cells such as macrophages, mast cells and dendritic cells, thus accelerating cell death and apoptosis of hair follicle cells (Bertolini, M, 2020).

[0033] The initial clinical manifestations of AA appear as random, patchy hair loss - which may result in hair loss over the entire scalp (alopecia totalis) or may be generalized to all parts of the body (alopecia universalis). AA affects patients of all ethnicities, but with similar clinical symptoms, it affects women more than men. Most importantly, when AA begins early in infancy, its prognosis is usually grimmer and there is a higher frequency of unpredictable recurrences in adulthood (Villasante Fricke, AC, 2015).

[0034] In one embodiment, a subject in need thereof is a subject suffering from mild AA (SALT score <25), moderate AA (SALT score is 25-50), or severe AA (SALT score is 50-95). Preferably, a subject suffering from alopecia totalis / alopecia universalis (SALT score >95) is not a subject in need thereof according to the present invention, and the compositions of the present invention are not intended to be used to treat such alopecia totalis / alopecia universalis.

[0035] As used herein, the term "effective amount" means a therapeutically effective amount of a composition, pharmaceutical composition, therapeutic agent, active ingredient, compound, etc. of the present disclosure that is high enough to significantly positively alter the symptoms and / or condition being treated, yet low enough to avoid serious side effects (a reasonable risk / benefit ratio), within the scope of sound medical judgment.

[0036] In the context of the present invention, the composition of the present invention comprises as active ingredients effective amounts of an extract of an Allium species, an extract of a Citrus species, an extract of a Paullinia species and an extract of a Theobroma species.

[0037] The term "extract or hydroalcoholic extract of Allium species" refers in particular to hydroalcoholic extracts and natural extracts obtained from all species of the Allium genus (Liliaceae), in particular from onion (Allium cepa).

[0038] The term "extract or hydroalcoholic extract of Citrus species" refers in particular to hydroalcoholic extracts and natural extracts obtained from all species of the genus Citrus (Rutaceae), in particular Citrus lemon.

[0039] The term "extract (atomized or non-atomized) or hydroalcoholic extract of Paullinia spp." refers in particular to hydroalcoholic extracts and natural extracts obtained from all species of the genus Paullinia spp. (family Sapindaceae), in particular from Guarana (Paullinia cupana).

[0040] The term "extract (atomized or non-atomized) or hydroalcoholic extract of Theobrama species" refers in particular to hydroalcoholic extracts and natural extracts obtained from all species of the genus Theobrama (family Malvaceae), in particular from cocoa (Theobroma cacao).

[0041] In one aspect of the invention, the composition of the invention or the composition used is typically administered topically to the external skin surface of the skull for a period of time necessary to detect one or more therapeutic effects, including slowing hair loss, stimulating hair growth, and / or increasing hair density.

[0042] The period necessary to detect one or more therapeutic effects is usually about 16 to about 48 weeks, preferably about 20 to about 40 weeks, more preferably about 20 to about 32 weeks, and even more preferably about 24 weeks.

[0043] Any method known in the art can be used to detect, monitor and / or reveal one or more therapeutic benefits, including slowing hair loss, stimulating hair growth and / or increasing hair density.

[0044] In one embodiment, one or more therapeutic effects are detected, monitored and / or revealed by measuring the Alopecia Severity Assessment Tool (SALT) score.

[0045] SALT scoring is a calculation based on a scoring system. The scalp is divided into four regions: the left side of the scalp, which represents 18% of the scalp surface area; the right side of the scalp, which represents 18% of the scalp surface area; the vertex, which represents 40% of the scalp surface area; and the occipital region, which represents 24% of the scalp surface area. The hair loss rate in each of the four scalp regions is measured independently by multiplying it by its respective coefficient (left and right: 0.18, respectively; vertex: 0.40; occipital: 0.24). The coefficient for each region varies depending on the location. The hair loss rates obtained for all four regions are then summed to calculate the final total hair loss rate (called the SALT score).

[0046] Olsen et al. also described a SALT score assessment that is more suitable for clinical trials. As shown in Figure 1, each region is further subdivided into four quadrants (5%+4%+4%+5%, 10%+10%+10%+10% or 6%+6%+6%+6%) according to the scalp area.

[0047] The hair loss rate of each quadrant is measured independently by multiplying it by its respective coefficient (0.04, 0.05, 0.06 or 0.1). The coefficient for each quadrant varies depending on the location (Figure 1). The hair loss rates of all four regions (16 quadrants) obtained are then summed to calculate the final total hair loss rate (called the SALT score).

[0048] Since many calculations are performed to obtain a final SALT score, and coefficients vary depending on the region, manual SALT scoring may be subject to error. Therefore, in one embodiment, SALT scoring is performed by computer. In a preferred embodiment, the SALT score evaluation described by Olsen is used to detect, monitor and / or reveal one or more therapeutic effects.

[0049] Typically, a subject's baseline SALT score is measured before starting administration of the compositions of the invention.

[0050] In one embodiment, a decrease in the detected SALT score of at least about 2% or more, at least about 5% or more, at least about 10% or more, at least about 15% or more, at least about 20% or more, at least about 30% or more, at least about 40% or more, or at least about 50% or more is detected compared to the subject's baseline SALT score, indicating that one or more therapeutic effects have been detected and administration of a composition of the invention is effective.

[0051] A decrease in SALT score of at least about 2% or more, at least about 5% or more, at least about 10% or more, at least about 15% or more, at least about 20% or more, at least about 30% or more, at least about 40% or more, or at least about 50% or more is detected, as compared to the subject's SALT score measured after the last administration of the composition, indicating that one or more therapeutic effects have been detected and persist after the topical administration has ceased. In some embodiments, one or more therapeutic effects persist or are even improved.

[0052] Typically, the compositions of the present invention are administered topically, preferably to the external skin surface of the skull, at least once daily, at least twice daily, or more.

[0053] Typically, about 0.5 ml to 2.5 ml of the composition is applied at least once a day, at least twice a day, or more than once to cover the entire scalp of the subject.

[0054] In one embodiment, the composition of the invention or composition for use comprises from about 65% to about 93% by weight of a hydroalcoholic extract of Allium spp., from about 5% to about 33% by weight of a hydroalcoholic extract of Citrus spp., from about 0.25% to about 2.5% by weight of a hydroalcoholic extract of Paulinia spp., and from about 0.25% to about 2.5% by weight of a hydroalcoholic extract of Theobrama spp.

[0055] In a preferred embodiment, the composition of the invention or the composition for use comprises from about 65% to about 93% by weight of a hydroalcoholic extract of onion, from about 5% to about 33% by weight of a hydroalcoholic extract of citrus lemon, from about 0.25% to about 2.5% by weight of a hydroalcoholic extract of guarana, and from about 0.25% to about 2.5% by weight of a hydroalcoholic extract of cocoa.

[0056] In an even more preferred embodiment, the composition of the invention or used comprises about 87% by weight of a hydroalcoholic extract of onion, about 12% by weight of a hydroalcoholic extract of citrus lemon, about 0.67% by weight of a hydroalcoholic extract of guarana, and about 0.67% by weight of a hydroalcoholic extract of cocoa.

[0057] In one embodiment, the composition of the present invention or the composition to be used further comprises about 0.05% by weight to about 8.0% by weight of sodium chloride and about 1% by weight to about 40% by weight of glycerin as an excipient, based on the total weight of the composition.

[0058] In one embodiment, the composition of the present invention or the composition to be used comprises about 0.05% by weight to about 8.0% by weight, preferably about 0.1% by weight to about 7.0% by weight, more preferably about 0.4% by weight to about 6.0% by weight, and even more preferably about 0.9% by weight to about 3% by weight of sodium chloride, based on the total weight of the composition.

[0059] In one embodiment, the composition of the present invention or the composition to be used comprises from about 1% by weight to about 20% by weight, preferably from about 1.2% by weight to about 15% by weight, more preferably from about 1.8% by weight to about 10% by weight, and even more preferably from about 2% by weight to about 5% by weight of glycerin, based on the total weight of the composition.

[0060] Compositions of the present invention suitable for topical administration include liquid or semi-liquid formulations suitable for skin penetration, such as solutions, lotions, shake lotions, creams, ointments, gels, foams, transdermal patches, powders, solids, sponges, tapes, vapors, pastes, tinctures, microparticles, microcapsules, nanoparticles, liposomes, emulsions, etc. Preferably, compositions of the present invention suitable for topical administration are in the form of a solution or lotion.

[0061] The present invention further contemplates a method of treating and / or preventing alopecia in a subject.

[0062] In one aspect, a method for treating and / or preventing alopecia in a subject comprises administering to a subject a composition comprising an effective amount of an extract of Allium spp., an extract of Citrus spp., an extract of Paulinia spp., and an extract of Theobrama spp. as active ingredients; The composition is administered topically for a period of time necessary to detect one or more therapeutic benefits, including slowing hair loss, stimulating hair growth, and / or increasing hair density; The one or more therapeutic effects persist for at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks or more following the last administration of the composition, as evidenced by measurement of the Severity of Alopecia Tool (SALT) score.

[0063] The invention further contemplates the use of the composition of the invention in the manufacture of a medicament for the treatment and / or prevention of alopecia in a subject, said use comprising administering a medicament comprising an effective amount of an extract of Allium spp., an extract of Citrus spp., an extract of Paulinia spp. and an extract of Theobrama spp. as active ingredients; The agent is administered topically for a period of time necessary to detect one or more therapeutic effects, including slowing hair loss, stimulating hair growth, and / or increasing hair density; The one or more therapeutic effects persist for at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks or more following the last administration of the composition, as evidenced by measurement of the Severity of Alopecia Tool (SALT) score.

[0064] The present invention also contemplates a kit for the treatment and / or prevention of alopecia as described herein. In one aspect of the invention, the kit comprises a composition of the invention or a composition for use.

[0065] The kits of the present invention may also include a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, dispensers, spray applicators, and the like. The containers can be formed from a variety of materials, such as glass or plastic.

[0066] A label or package insert may include instructions for its use. The included instructions may be affixed to the packaging material or included as a package insert. The instructions are typically, but are not limited to, written or printed. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this disclosure.

[0067] The present disclosure is to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein. EXAMPLES

[0068] Materials and Methods The composition (22.25%) was evaluated in a clinical trial evaluating the safety and efficacy of the composition in subjects with AA (RAAINBOW study, ClinicalTrials.gov identifier: NCT03240627). Approximately 1 mL of the composition was applied to the entire scalp twice daily, approximately 12 hours apart (e.g., in the morning and in the evening).

[0069] The RAAINBOW study was a double-blind, randomized, multicenter study compared with placebo. 107 subjects (male and female) were enrolled and safety analyses were performed. Of these subjects, 62 who met the inclusion criteria (i.e., moderate to severe AA) representing the full analysis set (FAS) were analyzed for efficacy.

[0070] result The safety analysis is outlined below.

[0071] [Table 1]

[0072] No subjects in the composition group experienced any serious adverse events (AEs). Only 5.6% of subjects treated with the composition had AEs that were possibly drug-related (vs. 11.1% in the placebo group). One AE was severe, consisting of severe scalp and facial eczema. However, eczema is the most common comorbidity in AA, and AA patients are more likely to suffer from atopic dermatitis and eczema (17.4% vs. 2.2% controls) (Conic, 2020). All other AEs were mild, moderate, localized, and transient.

[0073] The side effects observed with JAK inhibitors and corticosteroids were not reported in this study. The composition is so safe in treating AA that it does not require a treatment withdrawal period. Therefore, the composition can be used chronically without discontinuation and without risk to the user's health or risk of disease recurrence.

[0074] Additionally, the RAAINBOW study was specifically designed to evaluate not only the effectiveness of the composition against AA after 6 months of treatment, but also the likelihood of potential disease recurrence after cessation of treatment, measured 6 months after cessation of treatment.

[0075] AA was assessed by the Scalp Alopecia Areata Severity Score, known as the SALT (Alopecia Severity Tool) score, based on global standardized scalp photographs. The SALT score was developed in 2004 by Olsen "to facilitate well-controlled clinical trials in alopecia areata" (Olsen, 2004). It is a standardized method for assessing the extent of alopecia, with a SALT score of 100% being total hair loss. It is based on a scoring system based on four photographs, where each side of the head is divided into four quadrants and scored accordingly by the investigator (see Figure 1). The SALT score is a standardized measurement endpoint and is used in all trials evaluating the efficacy of new treatments for AA. An example is shown below.

[0076] In the RAAINBOW study, SALT scores (Figure 1) were measured at baseline (V1), after 3 months of treatment (V2), and after 6 months of treatment (V3). Treatment was then discontinued and patients' AA was reassessed after 3 months of treatment-free follow-up (V4) and after 6 months of treatment-free follow-up (V5).

[0077] After testing the normality assumption of the data (using both QQ plots and Shapiro-Wilk tests), a generalized linear model (GLIMMIX procedure in SAS) was preferred over the MMRM. The GLIMMIX model had rank of relative change from baseline in SALT score as the dependent variable, treatment, visit, and treatment-by-visit interaction as fixed effects, and baseline severity based on SALT score as a covariate.

[0078] There was a statistically significant difference between the LH-8 and placebo groups in terms of relative and absolute changes in SALT scores from baseline to week 24, with the LH-8 group showing a higher change, thus meeting the planned primary endpoint (p-value <0.0001).

[0079] Of subjects treated with the composition who improved over the 6-month treatment period (V1 through V3), only 4% experienced disease recurrence after treatment was discontinued, as measured after a 6-month treatment-free period (V5). 96% of subjects who responded to treatment did not recur after treatment was discontinued. Additionally, as shown in Figure 2, SALT scores in patients treated with the composition continued to improve, with changes in SALT scores continuing throughout the follow-up period and statistically significantly superior to placebo.

[0080] In chronic diseases, a 6-month period is considered representative of disease progression (Ostbye, 2005). Therefore, a 6-month treatment-free follow-up period is considered representative of the long-term progression of the disease (Figure 2).

[0081] In this case, it can be concluded that, except for 4% of cases, cessation of treatment with the composition did not lead to recurrence of the disease. Thus, unlike treatment with JAK inhibitors, corticosteroids, treatment with the composition does not require cessation for safety reasons, but can be discontinued without risk of disease recurrence. AA is a chronic disease that requires chronic treatment, but the composition allows the disease to be treated only until it is controlled, not in a chronic manner, and then treatment can be safely discontinued. This represents a new way of treating AA.

[0082] References

Table 2

Claims

1. 1. A composition for use in treating and / or preventing alopecia in a subject, comprising an effective amount of an extract of Allium spp., an extract of Citrus spp., an extract of Paulinia spp., and an extract of Theobrama spp. as active ingredients, the composition comprising: The composition is administered topically for a period of time necessary to detect one or more therapeutic benefits, including slowing hair loss, stimulating hair growth, and / or increasing hair density; The composition used, wherein the one or more therapeutic effects persist for at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks or more after the last administration of the composition, as evidenced by measurement of the Alopecia Severity Assessment Tool (SALT) score.

2. The composition of claim 1, wherein the alopecia is an immune-mediated disease.

3. The method of claim 2, wherein the immune-mediated disease is an autoimmune disease.

4. The method according to claim 3, wherein the autoimmune disease is alopecia areata.

5. The composition used according to any one of claims 1 to 4, wherein the period required to detect one or more therapeutic effects is about 16 to about 48 weeks, preferably about 20 to about 40 weeks, more preferably about 20 to about 32 weeks, and even more preferably about 24 weeks.

7. The use of a composition according to any one of claims 1 to 6, wherein the one or more therapeutic effects are detected or revealed by measuring the Alopecia Severity Tool (SALT) score.

8. The composition for use according to any one of claims 1 to 7, wherein a decrease in SALT score of at least about 2% or more, at least about 5% or more, at least about 10% or more, at least about 15% or more, at least about 20% or more, at least about 30% or more, at least about 40% or more, or at least about 50% or more is detected in the subject as compared to the subject's baseline SALT score measured before administration of the composition was started.

9. The composition for use according to any one of claims 1 to 8, wherein a decrease in the SALT score of at least about 2% or more, at least about 5% or more, at least about 10% or more, at least about 15% or more, at least about 20% or more, at least about 30% or more, at least about 40% or more, or at least about 50% or more is detected when compared to the subject's SALT score measured after the last administration of the composition.

10. 10. The composition for use according to any one of claims 1 to 9, comprising from about 65% to about 93% by weight of a hydroalcoholic extract of Allium spp., from about 5% to about 33% by weight of a hydroalcoholic extract of Citrus spp., from about 0.25% to about 2.5% by weight of a hydroalcoholic extract of Paulinia spp., and from about 0.25% to about 2.5% by weight of a hydroalcoholic extract of Theobrama spp.

11. 11. The composition used according to any one of claims 1 to 10, comprising from about 65% to about 93% by weight of a hydroalcoholic extract of onion, from about 5% to about 33% by weight of a hydroalcoholic extract of citrus lemon, from about 0.25% to about 2.5% by weight of a hydroalcoholic extract of guarana, and from about 0.25% to about 2.5% by weight of a hydroalcoholic extract of cocoa.

12. 12. The composition used according to claim 11, comprising about 87% by weight of a hydroalcoholic extract of onion, about 12% by weight of a hydroalcoholic extract of citrus lemon, about 0.67% by weight of a hydroalcoholic extract of guarana, and about 0.67% by weight of a hydroalcoholic extract of cocoa.

13. The composition for use according to any one of claims 1 to 12, further comprising about 0.05% to about 8.0% by weight of sodium chloride and about 1% to about 40% by weight of glycerin as excipients, based on the total weight of the composition.

14. 14. The composition used according to claim 13, comprising from about 0.05% to about 8.0% by weight, preferably from about 0.1% to about 7.0% by weight, more preferably from about 0.4% to about 6.0% by weight, and even more preferably from about 0.9% to about 3% by weight of sodium chloride, based on the total weight of the composition.

15. 15. The composition used according to claim 13 or 14, comprising from about 1% to about 20%, preferably from about 1.2% to about 15%, more preferably from about 1.8% to about 10%, and even more preferably from about 2% to about 5% by weight of glycerin, based on the total weight of the composition.

Citation Information

Patent Citations

  • Hair growth stimulation methods

    JP2013532720A

  • Novel use of compositions for preventing chemotherapy and radiotherapy-induced alopecia (CRIA), reducing the impact of CRIA, and improving the appearance of hair regrowth after CRIA.

    JP2014506586A

  • New use of compositions to delay the onset of the catagen phase of the hair

    WO2013020719A2